Illumina (ILMN) Optics for Genomics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Illumina (ILMN) Optics for Genomics

ILMN 121.07

-1.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (27)	5/20/2002 8:43:55 PM
From: mopgcw	Read Replies (1) of 276

Illumina Doubles Oligator DNA Synthesis Capacity and Launches $0.16 Per Base Oligo Pricing SAN DIEGO--(BW HealthWire)--May 20, 2002--Illumina, Inc. announced today that it has expanded DNA synthesis capacity to over 10 million oligonucleotides (oligos) per year, doubling previous capacity and allowing $0.16 per base customer pricing -- 11% lower than previous levels. Leveraging proprietary Oligator(TM) technology, the additional capacity is earmarked for large-volume users in the plate-sized oligo market, a segment that is growing rapidly due to the accelerated pace and expanded scale of genomic studies. Illumina also uses oligos for its genotyping services business built on the BeadArray(TM) technology platform and for the assembly of Sentrix(TM) bead-based microarray product offerings. "Our Oligator technology is both robust and scalable," stated Jay Flatley, Illumina President and CEO. "We have doubled oligo capacity with only incremental capital improvements, enabling us to further reduce unit manufacturing costs and continue to execute our price leadership strategy. With our new $0.16 per base pricing for standard products, customers benefit from exceptional oligonucleotide product quality at industry-leading prices." Availability of inexpensive oligos is fundamental to the development of many genomic applications including high-throughput SNP genotyping. For example, the detection of just one SNP (single nucleotide polymorphism) requires three to five oligos depending on the assay technique, and there are millions of SNPs in the human genome alone. SNP genotyping is emerging as a key method for understanding genetic variation between individuals. Genetic differences help determine individuals' predisposition to disease as well as response to and dosage rates for different drugs. Illumina (Nasdaq: ILMN; www.illumina.com) is developing next-generation tools that permit large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology will provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. Parties interested in Illumina's oligonucleotides may visit www.oligator.com/NRgator for additional information.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next